108 Chapter 5 Table S1. Treatment-related adverse events (trAE) in all treated patients (N=31), ≥5% for any grade, ≥2% for grade 3-4. Any grade Grade 3-4 Patients with any trAE, n(%) 27 (87%) 13 (48%) Bleeding 5 (19%) 2 (15%) Diarrhea or constipation 9 (33%) - Elevated AST/ALT 6 (22%) 3 (23%) Elevated AF 2 (7%) 1 (8%) Elevated GGT 3 (11%) 1 (8%) Elevated creatinine (1x nephritis) 3 (11%) 1 (8%) Fatigue 12 (44%) - Hyperglycaemia 2 (7%) 1 (8%) Hypo- or hyperthyroidism 5 (19%) - Hyponatremia 3 (11%) 1 (8%) Hearing loss 1 (4%) 1 (8%) Peripheral sensory neuropathy 2 (7%) - Myalgia 4 (15%) - Rash 3 (11%) - Respiratory tract (2x pneumonitis) 13 (48%) 3 (23%) Thrombocytopenia 1 (4%) 1 (8%) Overall, 27 patients (87%) reported a trAE. Four patients died, of treatment unrelated event; one following a spondylodiscitis and one other patients due to trauma. Two patients died from a covid-19 infection.
RkJQdWJsaXNoZXIy MTk4NDMw